Skip to content
Head to head

GH Research vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: GHRS · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

GHRS +24.3%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals earns the most per share.
GHRSVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price17.53515.02
Change today-5.55%-1.08%
1-year return+25.3%+22.0%
Market cap$1.20B$130.58B
52-week range12.04 – 31.44412.27 – 568.67
Valuation
P/E (TTM)-18.6533.14
P/E percentile, own 5-yr range53rd99th
P/B3.456.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.7915.32
Net profit (TTM)$-54.25M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-06-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-51.84M$3.20B
Provider cash-flow period date2026-06-292026-09-29
Ownership & sentiment
Institutional ownership73.4%96.8%
Insider activity (12mo)4 buy / 0 sell28 buy / 22 sell
Short interest (% of float)3.0%1.9%
Analyst consensus100% buy (3)95% buy / 5% hold (21)
Analyst price target$50 (+187%)$624 (+21%)
StockVane view
StockVane Quant RatingD (67)C (68)
Company
Employees736,400
Founded20211989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.